Serum NLR combined with CA125 and HE4 improves the diagnostic and prognostic efficiency in patients with ovarian cancer
BackgroundOvarian cancer (OC) represents a common neoplasm within the female reproductive tract. The prognosis for patients diagnosed at advanced stages is unfavorable, primarily attributable to the absence of reliable screening markers for early detection. An elevated neutrophil-to-lymphocyte ratio...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1494051/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841527523485155328 |
|---|---|
| author | Yun Tian Yun Tian Xiabing Li Xiabing Li Hongjian Zhang Hongjian Zhang Yaping Wang Yaping Wang Hongyu Li Hongyu Li Qiaohong Qin Qiaohong Qin |
| author_facet | Yun Tian Yun Tian Xiabing Li Xiabing Li Hongjian Zhang Hongjian Zhang Yaping Wang Yaping Wang Hongyu Li Hongyu Li Qiaohong Qin Qiaohong Qin |
| author_sort | Yun Tian |
| collection | DOAJ |
| description | BackgroundOvarian cancer (OC) represents a common neoplasm within the female reproductive tract. The prognosis for patients diagnosed at advanced stages is unfavorable, primarily attributable to the absence of reliable screening markers for early detection. An elevated neutrophil-to-lymphocyte ratio (NLR) serves as an indicator of host inflammatory response and has been linked to poorer overall survival (OS) across various cancer types; however, its examination in OC remains limited. This study seeks to identify combination diagnostic and prognostic markers for OC, aiming to improve diagnostic and prognostic efficacy, especially in the early stages.MethodsWe analyzed the targeted biomarkers in a cohort of 104 OC patients and 100 controls, which comprised 50 patients with benign ovarian tumors and 50 healthy women, using enzyme-linked immunosorbent assay (ELISA) and complete blood counting (CBC). After validating the biomarker panel, we compared the expression levels of the biomarkers in OC patients with various clinical features to assess their relevance. A biomarker panel was developed and validated with an independent cohort of 70 OC patients and 60 controls, including 30 with benign ovarian tumors and 30 healthy women. We evaluated the diagnostic accuracy using the area under the receiver-operating characteristic (ROC) curve and overall survival analysis was used for prognosis.ResultsThe results from ELISA and CBC analyses indicated that the NLR was significantly higher in patients with OC. This elevation was especially notable in those with advanced stages of the disease, lymph node metastasis, and ascites. The diagnostic performance of the NLR, when combined with CA125 and HE4, outperformed each marker used individually, especially when compared to the traditional combination of CA125 and HE4. Importantly, we observed similar results in patients with early-stage ovarian cancer and those with low levels of CA125 and HE4. In addition, these results suggest that NLR combined with CA125 and HE4 levels in OC patients have significant prognostic value.ConclusionsThe effective combination of serum NLR, CA125, and HE4 significantly enhances diagnostic efficiency in patients with OC. Serum NLR, CA125, and HE4 levels were identified as independent prognostic markers for OC. |
| format | Article |
| id | doaj-art-8849fd1b330643ee84e6bb71095d1e73 |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-8849fd1b330643ee84e6bb71095d1e732025-01-15T14:14:58ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2024-12-011410.3389/fonc.2024.14940511494051Serum NLR combined with CA125 and HE4 improves the diagnostic and prognostic efficiency in patients with ovarian cancerYun Tian0Yun Tian1Xiabing Li2Xiabing Li3Hongjian Zhang4Hongjian Zhang5Yaping Wang6Yaping Wang7Hongyu Li8Hongyu Li9Qiaohong Qin10Qiaohong Qin11Gynecologic Oncology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, ChinaZhengzhou Key Laboratory of Gynecological Oncology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, ChinaGynecologic Oncology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, ChinaZhengzhou Key Laboratory of Gynecological Oncology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, ChinaGynecologic Oncology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, ChinaZhengzhou Key Laboratory of Gynecological Oncology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, ChinaGynecologic Oncology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, ChinaZhengzhou Key Laboratory of Gynecological Oncology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, ChinaGynecologic Oncology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, ChinaZhengzhou Key Laboratory of Gynecological Oncology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, ChinaGynecologic Oncology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, ChinaZhengzhou Key Laboratory of Gynecological Oncology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, ChinaBackgroundOvarian cancer (OC) represents a common neoplasm within the female reproductive tract. The prognosis for patients diagnosed at advanced stages is unfavorable, primarily attributable to the absence of reliable screening markers for early detection. An elevated neutrophil-to-lymphocyte ratio (NLR) serves as an indicator of host inflammatory response and has been linked to poorer overall survival (OS) across various cancer types; however, its examination in OC remains limited. This study seeks to identify combination diagnostic and prognostic markers for OC, aiming to improve diagnostic and prognostic efficacy, especially in the early stages.MethodsWe analyzed the targeted biomarkers in a cohort of 104 OC patients and 100 controls, which comprised 50 patients with benign ovarian tumors and 50 healthy women, using enzyme-linked immunosorbent assay (ELISA) and complete blood counting (CBC). After validating the biomarker panel, we compared the expression levels of the biomarkers in OC patients with various clinical features to assess their relevance. A biomarker panel was developed and validated with an independent cohort of 70 OC patients and 60 controls, including 30 with benign ovarian tumors and 30 healthy women. We evaluated the diagnostic accuracy using the area under the receiver-operating characteristic (ROC) curve and overall survival analysis was used for prognosis.ResultsThe results from ELISA and CBC analyses indicated that the NLR was significantly higher in patients with OC. This elevation was especially notable in those with advanced stages of the disease, lymph node metastasis, and ascites. The diagnostic performance of the NLR, when combined with CA125 and HE4, outperformed each marker used individually, especially when compared to the traditional combination of CA125 and HE4. Importantly, we observed similar results in patients with early-stage ovarian cancer and those with low levels of CA125 and HE4. In addition, these results suggest that NLR combined with CA125 and HE4 levels in OC patients have significant prognostic value.ConclusionsThe effective combination of serum NLR, CA125, and HE4 significantly enhances diagnostic efficiency in patients with OC. Serum NLR, CA125, and HE4 levels were identified as independent prognostic markers for OC.https://www.frontiersin.org/articles/10.3389/fonc.2024.1494051/fullovarian cancerdiagnosisNLRCA125HE4prognosis |
| spellingShingle | Yun Tian Yun Tian Xiabing Li Xiabing Li Hongjian Zhang Hongjian Zhang Yaping Wang Yaping Wang Hongyu Li Hongyu Li Qiaohong Qin Qiaohong Qin Serum NLR combined with CA125 and HE4 improves the diagnostic and prognostic efficiency in patients with ovarian cancer Frontiers in Oncology ovarian cancer diagnosis NLR CA125 HE4 prognosis |
| title | Serum NLR combined with CA125 and HE4 improves the diagnostic and prognostic efficiency in patients with ovarian cancer |
| title_full | Serum NLR combined with CA125 and HE4 improves the diagnostic and prognostic efficiency in patients with ovarian cancer |
| title_fullStr | Serum NLR combined with CA125 and HE4 improves the diagnostic and prognostic efficiency in patients with ovarian cancer |
| title_full_unstemmed | Serum NLR combined with CA125 and HE4 improves the diagnostic and prognostic efficiency in patients with ovarian cancer |
| title_short | Serum NLR combined with CA125 and HE4 improves the diagnostic and prognostic efficiency in patients with ovarian cancer |
| title_sort | serum nlr combined with ca125 and he4 improves the diagnostic and prognostic efficiency in patients with ovarian cancer |
| topic | ovarian cancer diagnosis NLR CA125 HE4 prognosis |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1494051/full |
| work_keys_str_mv | AT yuntian serumnlrcombinedwithca125andhe4improvesthediagnosticandprognosticefficiencyinpatientswithovariancancer AT yuntian serumnlrcombinedwithca125andhe4improvesthediagnosticandprognosticefficiencyinpatientswithovariancancer AT xiabingli serumnlrcombinedwithca125andhe4improvesthediagnosticandprognosticefficiencyinpatientswithovariancancer AT xiabingli serumnlrcombinedwithca125andhe4improvesthediagnosticandprognosticefficiencyinpatientswithovariancancer AT hongjianzhang serumnlrcombinedwithca125andhe4improvesthediagnosticandprognosticefficiencyinpatientswithovariancancer AT hongjianzhang serumnlrcombinedwithca125andhe4improvesthediagnosticandprognosticefficiencyinpatientswithovariancancer AT yapingwang serumnlrcombinedwithca125andhe4improvesthediagnosticandprognosticefficiencyinpatientswithovariancancer AT yapingwang serumnlrcombinedwithca125andhe4improvesthediagnosticandprognosticefficiencyinpatientswithovariancancer AT hongyuli serumnlrcombinedwithca125andhe4improvesthediagnosticandprognosticefficiencyinpatientswithovariancancer AT hongyuli serumnlrcombinedwithca125andhe4improvesthediagnosticandprognosticefficiencyinpatientswithovariancancer AT qiaohongqin serumnlrcombinedwithca125andhe4improvesthediagnosticandprognosticefficiencyinpatientswithovariancancer AT qiaohongqin serumnlrcombinedwithca125andhe4improvesthediagnosticandprognosticefficiencyinpatientswithovariancancer |